Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Researchers have discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement system, a key component of early antiviral immunity. This significantly ...
Health on MSN
What's the life expectancy for complement 3 glomerulopathy—and how does it affect quality of life?
Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the ...
C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...
In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte ...
Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...
Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results